Table 4.
Clinical trials on different AR-targeted therapies in recent 5 years
| Agents | Additional treatment | Trial phase | Identifier | First post |
|---|---|---|---|---|
| PROTAC | ||||
| ARV-110 | Enzalutamide, Abiraterone | Phase 1/2 | NCT03888612 | 2019 |
| Abiraterone | Phase 1 | NCT05177042 | 2022 | |
| AR antagonist (targeting other domains of the AR) | ||||
| EPI-506 (NTD) | None | Phase 1/2 | NCT02606123 | 2015 |
| Androgen synthesis inhibitor | ||||
| Abiraterone | ADT, Prednisone | Phase 3 | NCT01715285 | 2012 |
| Olaparib | Phase 2 | NCT01972217 | 2013 | |
| ADT, Docetaxel | Phase 3 | NCT01957436 | 2013 | |
| Apalutamide | Phase 3 | NCT02257736 | 2014 | |
| Ipatasertib, Prednisolone | Phase 3 | NCT03072238 | 2017 | |
| Orteronel | Prednisone | Phase 3 | NCT01193244 | 2010 |
| None | Phase 3 | NCT01707966 | 2012 | |
| Galeterone | None | Phase 2 | NCT01709734 | 2012 |
| None | Phase 3 | NCT02438007 | 2015 | |
| AR agonist | ||||
| Testosterone | Nivolumab | Phase 2 | NCT03554317 | 2018 |
| Carboplatin | Phase 2 | NCT03522064 | 2018 | |
| Darolutamide | Phase 2 | NCT04558866 | 2020 | |
| Rucaparib | Phase 3 | NCT04455750 | 2020 | |
| Enzalutamide | Phase 2 | NCT05081193 | 2021 | |
| None | Phase 2 | NCT05011383 | 2021 | |
| Olaparib | Phase 2 | NCT03516812 | 2022 | |
| Fluorinated DHT | None | Phase 1 | NCT01724619 | 2012 |